Inclusion Criteria:

• Age ≥ 18 years old.
• Life expectancy ≥ 6 months.
• Patients with Common Terminology Criteria for Adverse Events (CTCAE) Grade 0 CIPN (exception, patients with multiple myeloma treated with bortezomib, CTCAE Grade <=1)
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
• Breast cancer only:
  • Breast cancer beginning treatment with paclitaxel or docetaxel with curative intent 
• Lymphoma only:
  • Incident lymphoma initiating treatment with vincristine.
  • Planned minimum of four cycles of chemotherapy.
• Oxaliplatin-based regimens, Stage III colorectal cancer: Total of 6 months (12 cycles)
• Bortezomib use in untreated multiple myeloma: Total of 4 months (9 cycles)
• Enrollment must be completed prior to receiving the first dose of neurotoxic chemotherapy.

Exclusion Criteria:

• Evidence of central nervous system metastases.
• Evidence of clinically significant peripheral neuropathy [CTCAE >2] as defined by patient report of frequent numbness or tingling in the hands or feet.
• Any uncontrolled serious illness or medical condition that would impact the conduct of the current study. 
• Previous exposure to neurotoxic chemotherapy drugs (such as Platins, taxane, vinca alkaloids, epothilones, proteasome inhibitors, or immunomodulatory drugs).
• Pre-existing neurodegenerative disease (Parkinson's, Alzheimer's, Huntington's, etc.), neuromuscular disorder (multiple sclerosis, ALS, polio, hereditary neuromuscular disease) or history of stroke or history of traumatic brain injury.
• General anesthesia less than one month prior to enrollment.